Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IAVI C108: rVSVΔG-SEBOV-GP Vaccine Phase 1
NCT05724472Phase 1Completed
- Sponsor
- International AIDS Vaccine Initiative
- Start
- Jun 2023
- Primary completion
- Jan 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of rVSV-SUDV-GP in Sudan virus disease (SVD) (3 arms), sponsored by International AIDS Vaccine Initiative. Primary endpoint: Safety and tolerability of rVSVΔG-SEBOV-GP vaccine at 14 days. Started Jun 2023; status: completed.
02
Drugs
rVSV-SUDV-GP
03
Conditions
Sudan virus disease (SVD)
Beyond the preview
Go deeper on NCT05724472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05724472.